ロード中...

AT-06 A PHASE II TRIAL OF TAMOXIFEN AND BORTEZOMIB IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA

BACKGROUND: Preclinical studies indicated that inhibition of NF-kB with bortezemib markedly enhance tamoxifen-mediated glioma apoptosis. A potentially synergistic cytotoxic effect of the combination may benefit patients with malignant gliomas. METHODS: We conducted single institution phase II trial...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Aregawi, Dawit, Kreisl, Teri N., Innis, Ellen, Fine, Howard A.
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2014
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217841/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.6
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!